68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC

This is a phase II clinical trial to evaluate the capability of 68Ga-labeled targeted covalent radiopharmaceutical (TCR) fibroblast activation protein inhibitor (FAPI) PET/CT to guide the surgical treatment of medullary thyroid carcinoma (MTC). The surgical extent of MTC is determined based on the lesion range revealed by 68Ga-TCR-FAPI PET/CT, with the main endpoint being 1-month post-surgical calcitonin level.

Trial Details

NCT ID
NCT06277180
Phase
NA
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
RECRUITING
Cancer Type
Thyroid Cancer
Interventions
  • Surgery
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Age between 18 and 75 years；
  • Diagnosed with MTC and have surgical indication based on preliminary evaluation; the tumor may be newly diagnosed or previously treated;
  • Expected survival of at least 12 weeks;
  • No major organ dysfunction (heart, lung, liver, kidney and other major organ include), acute or life-threatening status of infection;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Thyroid Cancer Trials on Trialify →